These innovative SNAP cartridges provide greater compound purity and sample loading, increased compound recovery and reduced waste.
The new SNAP HP-SIL cartridges employ 30 µm silica, which provides tighter elution bands for increased fraction purity and up to two times more loading capacity than traditional flash cartridges. Requiring fewer cartridges and less solvent usage, the Biotage SNAP high performance cartridges enable scientists to speed up throughput and achieve better separations.
The smaller 30 µm particle size silica in the new SNAP HP-SIL cartridge reduces the interstitial volume, improving separations for compounds with low CV values. Additionally, the SNAP cartridges' Luer-lok connections require no compression modules or adapter kits, which further reduces costs, improving ease-of-use. The rugged design of Biotage's new cartridges provides pressure stability of 100 psi (7 bar). SNAP cartridges are available in five popular sizes: 10g, 25g, 50g, 100g and 340g.
Biotage SNAP HP-SIL cartridges are also environmentally friendly. Biotage has published a new application note demonstrating how the SNAP HP-SIL cartridges can reduce solvent consumption by 41% and purification time by 72% over a traditional flash cartridge. The application note, entitled Get better separations in less time, using less solvent, with SNAP HP-SIL high performance flash cartridges is available by e-mail.
For further press information please contact: Eleanor CallanMonk, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, E: biotage[.]scottpr.com.
Biotage (biotage.com) is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the areas of genetic analysis and medicinal chemistry. In 2005 operations and products were acquired from the American company Argonaut, further strengthening the medicinal chemistry product range. The customers include the worlds top 30 pharmaceutical companies, the worlds top 20 biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has offices in the U.S., Japan, UK, Germany and several other European countries. Biotage has 336 employees and had sales of 496,4 MSEK in 2007. Biotage is listed on the OMX Nordic Exchange Stockholm AB.
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," and "should," among others. These forward-looking statements are based on Biotage's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Biotage notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the microwave synthesis and flash purification in the drug discovery market, DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Biotage's products (including seasonal fluctuations), difficulties in successfully adapting the Company's products to integrated solutions and producing such products, and the Company's ability to identify and develop new products and to differentiate its products from competitors.